<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR60.html">Part 60
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 60.26  Final action on regulatory review period determinations.
                            </h3>
                            <p class="depth1"><em>(a)</em> FDA will consider a regulatory review period determination to be  final upon expiration of the 180-day period for filing a due diligence  petition under Sec. 60.30 unless FDA receives:</p><p class="depth2"><em>(1)</em> New information from PTO records, FDA records, or FDA centers  that affects the regulatory review period determination;</p><p class="depth2"><em>(2)</em> A request under Sec. 60.24 for revision of the regulatory  review period determination;</p><p class="depth2"><em>(3)</em> A due diligence petition filed under Sec. 60.30; or</p><p class="depth2"><em>(4)</em> A request for a hearing filed under Sec. 60.40.</p><p class="depth1"><em>(b)</em> FDA will notify PTO that the regulatory review period  determination is final upon:</p><p class="depth2"><em>(1)</em> The expiration of the 180-day period for filing a due diligence  petition; or</p><p class="depth2"><em>(2)</em> If FDA has received a request for a revision, a due diligence  petition, or a request for a hearing, upon resolution of the request for  a revision, the petition, or the hearing, whichever is later. FDA will  send a copy of the notification to the applicant and file a copy of the  notification in the docket established for the application in FDA's  Division of Dockets Management (HFA-305), 5630 Fishers Lane, rm. 1061,  Rockville, MD 20852.  [53 FR 7305, Mar. 7, 1988, as amended at 59 FR 14364, Mar. 28, 1994]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
